AMYT EC approval | Biotech Message Board Posts


Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  42040 of 42557  at  6/23/2022 7:47:43 AM  by

minxmrphd


AMYT EC approval

 

07:44 AM EDT, 06/23/2022 (MT Newswires) -- Amryt Pharma (AMYT) said Thursday that the European Commission approved Filsuvez in the European Union for the treatment of partial thickness wounds related to dystrophic and junctional epidermolysis bullosa in patients age 6 months and older.

Epidermolysis bullosa is a rare genetic skin disorder in young children and adults for which there has been no approved treatment as of yet, the company noted.

The approval of Filsuvez is backed by phase 3 data from the company's EASE trial with patients across 58 sites in 28 countries.

Amryt's shares were up almost 5% in premarket trading on Thursday morning.

Price: 7.19, Change: +0.34, Percent Change: +4.96



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 5  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...